Perioperative management and anaesthetic considerations for adult patients with Gilbert's syndrome and oral cancer: review and case report

Gilbert's syndrome is the most common cause of hereditary hyperbilirubinemia and poses a clinical challenge for anaesthesiologists. The decreased activity of bilirubin uridine glucuronyl transferase can lead to toxicity for usual doses of most anaesthetic agents. We review and discuss the appro...

Full description

Saved in:
Bibliographic Details
Published in:Biotechnology, biotechnological equipment biotechnological equipment, 2019-01, Vol.33 (1), p.1182-1186
Main Authors: Tzoneva, Dochka, Aleksiev, Evgeniy, Michova, Kalina, Stanimirov, Pavel
Format: Article
Language:English
Subjects:
anaesthesia
Analgesia
Anesthesia
Bilirubin
Blood flow
Case reports
Dehydration
Drugs
Gilbert's syndrome
Hyperbilirubinemia
Hypoglycemia
Management
Maxillofacial
maxillofacial surgery
oral cancer
Pain perception
Patients
Surgery
Toxicity
Uridine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gilbert's syndrome is the most common cause of hereditary hyperbilirubinemia and poses a clinical challenge for anaesthesiologists. The decreased activity of bilirubin uridine glucuronyl transferase can lead to toxicity for usual doses of most anaesthetic agents. We review and discuss the approach to successful and safe anaesthesia management in these patients and we report a case of a 48-year-old male patient with Gilbert's syndrome submitted to maxillofacial surgery under general anaesthesia. The recommended approach for the most successful and safe anaesthesia management in such patients includes the following: (i) minimizing the period of fasting to avoid hypoglycemia and dehydration; (ii) decreasing the perioperative stress by providing anxiolysis and adequate analgesia; (iii) avoiding hepatotoxic drugs and drugs predominantly metabolized by the liver; (iv) maintaining the hepatic blood flow; and (v) reduce polypharmacy.
ISSN:1310-2818
1314-3530
DOI:10.1080/13102818.2019.1649987